Akt and p53R2, partners that dictate the progression and invasiveness of cancer

Yousefi, Bahman; Samadi, Nasser; Ahmadi, Yasin

doi:10.1016/j.dnarep.2014.07.001

Cited by 44 publications

(26 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case of certain other anticancer drugs, SLC7A11 suppresses the expression of the proteins that are targets for the drugs. For example, gemcitabine in the form of its diphosphate produces its anticancer effects by inhibiting ribonucleotide reductase; SLC7A11 reverses this effect by directly activating the enzyme with glutathione or inducing the expression of the enzyme with glutathione-dependent activation of p53 (35,36). Therefore, pharmacologic blockade of the transport function of SLC7A11 not only interferes with tumor growth but also reverses resistance to certain chemotherapeutic agents.…”

Section: Slc7a11 and Its Functional Coupling To Slc1a5 In Cancer: Relmentioning

confidence: 99%

Amino Acid Transporters in Cancer and Their Relevance to “Glutamine Addiction”: Novel Targets for the Design of a New Class of Anticancer Drugs

et al. 2015

View full text Add to dashboard Cite

Tumor cells have an increased demand for amino acids because of their rapid proliferation rate. In addition to their need in protein synthesis, several amino acids have other roles in supporting cancer growth. There are approximately two-dozen amino acid transporters in humans, and tumor cells must upregulate one or more of these transporters to satisfy their demand for amino acids. If the transporters that specifically serve this purpose in tumor cells are identified, they can be targeted for the development of a brand new class of anticancer drugs; the logical basis of such a strategy would be to starve the tumor cells of an important class of nutrients. To date, four amino acid transporters have been found to be expressed at high levels in cancer: SLC1A5, SLC7A5, SLC7A11, and SLC6A14. Their induction occurs in a cancer typespecific manner with a direct or indirect involvement of the oncogene c-Myc. Further, these transporters are functionally coupled, thus maximizing their ability to promote cancer growth and chemoresistance. Progress has been made in preclinical studies, exploiting these transporters as drug targets in cancer therapy. These transporters also show promise in development of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemotherapeutic agents. Cancer Res; 75(9);

show abstract

Section: Slc7a11 and Its Functional Coupling To Slc1a5 In Cancer: Relmentioning

confidence: 99%

Amino Acid Transporters in Cancer and Their Relevance to “Glutamine Addiction”: Novel Targets for the Design of a New Class of Anticancer Drugs

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[43,44] AMPK is the key enzyme that regulates glucose homeostasis, lipid metabolism, and insulin sensitivity. [49,52,53] Similarly, metformin treatment has been proved to have chemo-preventive effects in ovarian cancer cells. [45] 2-Indirect activation occurs when upstream kinases such as liver kinase B1 (LKB-1) phosphorylates the catalytic domain of AMPK ( Figure 2).…”

Section: Biguanidesmentioning

confidence: 99%

New insights into antidiabetic drugs: Possible applications in cancer treatment

et al. 2017

Self Cite

View full text Add to dashboard Cite

Globally at 2014, it was estimated that there was 347 million people with diabetes in which 90 percent of them were diagnosed with type 2 diabetes mellitus (T2DM). Although the association between diabetes mellitus and cancer risk was found about 100 years ago, the issue is not still clear. Many studies especially cohort and case-control studies have suggested a higher risk of cancer in patients with diabetes mainly in those with type 2 diabetes. Insulin concentration is high in these patients, and due to its mitogenic effects, it may be a possible hypotheses for higher risk of cancer in diabetic patients. Therefore, antidiabetic drugs, which are involved in insulin secretion and sensitivity, may have beneficial effects in cancer treatment. Several groups of drugs with different mechanisms of action, mostly prescribed orally, are used for the treatment of type 2 diabetes mellitus including, insulin sensitizers (thiazolidinediones), insulin secretagogues (sulfonylureas), and biguanides. In this review, the possible effects of antidiabetic drugs (biguanides, thiazolidinediones, and sulfonylureas) and some of their mechanisms for overcoming cancer will be discussed.

show abstract

“…CAF‐expressed proteins are main links of CAFs with MDR (Figure ). Accumulating studies have shown that HGF signaling is involved in the progression of MDR by activating both MAPK and PI3K‐AKT signaling pathways and consequently inhibiting the drug‐induced apoptosis . Therefore, HGF signaling confers MDR via upregulation of AKT and MAPK signaling pathways.…”

Section: Resistance To Therapies Mediated By Breast Tumor Stromamentioning

confidence: 99%

Breast tumor stroma: A driving force in the development of resistance to therapies

Majidinia

Yousefi

2017

Chem Biol Drug Des

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most common cancer and the second leading cause of cancer-related death in women worldwide. In spite of huge advancements in early detection and ever-increasing knowledge of breast cancer biology, approximately 30% of patients with early-stage breast cancer experience disease recurrence. Most patients are chemosensitive and cancer free immediately after the treatment. About 50% to 70% of breast cancer patients, however, will relapse within 1 year. Such a relapse is usually concomitant with adenocarcinoma cells acquiring a chemoresistant phenotype. Both de novo and acquired chemoresistance are poorly understood and present a major burden in the treatment of breast cancer. Although, previously, chemoresistance was largely linked to genetic alterations within the cancer cells, recent investigations are indicating that chemoresistance can also be associated with the tumor microenvironment. Nowadays, it is widely believed that tumor microenvironment is a key player in tumor progression and response to treatment. In this study, we will review the interactions of breast tumor cells with their microenvironment, present the latest research on the resistance mediated by the stromal component in breast cancer, and discuss the potential therapeutic strategies that can be exploited to treat breast cancers by targeting tumor microenvironment.

show abstract

Akt and p53R2, partners that dictate the progression and invasiveness of cancer

Cited by 44 publications

References 73 publications

Amino Acid Transporters in Cancer and Their Relevance to “Glutamine Addiction”: Novel Targets for the Design of a New Class of Anticancer Drugs

Amino Acid Transporters in Cancer and Their Relevance to “Glutamine Addiction”: Novel Targets for the Design of a New Class of Anticancer Drugs

New insights into antidiabetic drugs: Possible applications in cancer treatment

Breast tumor stroma: A driving force in the development of resistance to therapies

Contact Info

Product

Resources

About